Psoriasis

In psoriasis, many therapies offer roughly the same level of care, but that doesn’t mean any patient will respond well to any therapy. According to Mark Lebwohl, M.D., physicians should consider each treatment option in light of a patient's specific comorbidities. 

Why do biologics lose efficacy over time? This physician discusses factors dermatologists should consider when they see this issue in their patients.

Continued psoriasis research has led to a translational revolution in inflammatory skin diseases. As a result, there are now a number of safer and more effective medications that can address a growing list of common immune-mediated skin diseases, such as atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa, acne, and rosacea.

More and more adults with psoriasis are using alternative remedies in place of traditional allopathic treatments, says a recent survey. One expert believes it’s due to undertreatment of the condition.

A recent study aimed to explore whether patients suffering from psoriasis carry serious medical morbidity, including cancer, that is not detected through history, physical exam and laboratory studies. 

According to a recent study, patients with psoriatic arthritis may be at a greater risk for adult hearing loss than individuals without psoriatic arthritis.

Unlike prior generations of dermatologic drugs, Janus kinase (JAK) inhibitors show potential for treating numerous dermatologic indications. Brett King, M.D., Ph.D. explored what this class of drug has to offer in his presentation during AAD earlier this month.

Researchers found a significant inverse correlation between ustekinumab levels and PASI scores at week 52, suggesting that drug levels are associated with the change in the treatment response. Measuring ustekinumab levels can have major clinical implications.

Guidelines suggest that providing a small test dose of methotrexate to patients followed by laboratory evaluation can minimize the risk of serious adverse events associated with methotrexate. This small retrospective study examined whether methotrexate requires a test dose.

Chief executive officer of Can-Fite Biopharmaceuticals, Pnina Fishman, Ph.D. discovered why cancer and inflammation can go everywhere in the body, except muscle tissue. Using this knowledge, Can-Fite has developed a promising psoriasis drug, piclidenoson, which is currently in phase 3 clinical trials.

With a crowded indication that includes 14 systemic agents, is there really room for tyrosine kinase 2 (Tyk2) inhibitors to treat psoriasis? This physician thinks so.

The development of new biologics targeting a variety of dermatoses is on the upswing with some treatments coming to the clinic as early as this year, according to April Armstrong, M.D. who discussed the topic at the American Academy of Dermatology Spring Meeting in Washington, D.C.

Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping. Andrew Blauvelt, M.D. discussed new drugs in the pipeline during American Academy of Dermatology Annual Meeting in Washington, D.C.

While this new class of medications still has a role in treating psoriasis, this physician says the standard for both their efficacy and safety is very high because of the existing, already very effective systemic therapies available today.

New guidelines from the American Academy of Dermatology and the National Psoriasis Foundation strongly support the use of a wide range of biologics to treat cases of psoriasis that are insufficiently resolved despite treatment with topical therapy, phototherapy or both. 

A decade ago, the list of psoriasis comorbidities didn't go much beyond psoriatic arthritis. Now, new guidelines warn dermatologists that many medical conditions are linked to psoriasis, from cardiovascular disease and metabolic syndrome to cancer, renal and hepatic disease and even the eye condition uveitis.

Researchers recently performed a control trial to test the efficacy of BMS-986165 a potent TYK2 inhibitor. Here's what they found.

Researchers at The Cleveland Clinic Lerner College of Medicine recently explored the development of a psoriasiform rash in patients with inflammatory bowel disease or rheumatoid arthritis who were treated with TNF-ɑ inhibitors. Learn what they discovered in this article.

A recent survey asks dermatologists who treat patients with moderate to severe psoriasis about the greatest unmet needs of this patient group. Here's what physicians had to say.

A recent study suggests that patients suffering from psoriasis and psoriatic arthritis may have an increased risk of developing autoimmune thyroid disease. 

Having psoriasis gives a patient a 1.75-fold increased odds of developing ulcerative colitis and a 1.70-fold increased odds of developing Crohn's disease.

Doctors should be vigilant about recognizing the signs and symptoms of patients who may develop ILD in order to prevent catastrophic complications, such as respiratory failure.

Increased mortality described in the first study to review all-cause mortality and cause-specific mortality in patients with psoriasis.

Sandoz, a division of Novartis, announced that the U.S. Food and Drug Administration approved its biosimilar, adalimumabadaz (Hyrimoz, Novartis AG). 

The National Psoriasis Foundation and the National Eczema Association have awarded Procter & Gamble’s Tide Free and Gentle Liquid Laundry Detergent and Tide PODS Free and Gentle Laundry Detergent a “Seal of Recognition” and “Seal of Acceptance” for people with eczema or sensitive skin.

The TNF alpha inhibitor certolizumab pegol (Cimzia, UCB) has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis.

Biologic tildrakizumab-asmn approved with suffix as differentiator from future biosimilar versions.

Wound healing is impaired in both psoriasis and multiple sclerosis. Understanding the pathophysiology of these two chronic conditions is vital to generating and improving treatment targets.

Patients with early-onset psoriasis are less likely than those with late-onset psoriasis to respond to systemic psoriasis treatments, a scientific review shows.

A review of more than 5,000 patients with moderate to severe plaque psoriasis who were treated with ixekizumab over three years, shows no unexpected safety signals.